ReviewPsychopharmacology2022
The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits.
Review in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Effect of ketamine on reward processing in depressive disorders: a systematic review of neuroimaging studies.CNS spectrums · 2026Pooled it
- Effects of Intravenous Ketamine on Posttraumatic Stress Disorder (PTSD): A Systematic Review.Acta psychiatrica Scandinavica · 2026Pooled it
- Subacute effects of ketamine on neural correlates of reward processing.Translational psychiatry · 2026Trial
- Depression in neurodegenerative disease: neurobiological mechanisms and emerging treatments.Molecular psychiatry · 2026Review
- Towards precision psychiatry: initial foundations and future directions.Nature reviews. Drug discovery · 2026Review
- Ketamine Improves Anhedonic Phenotypes Across Species: Translational Evidence From the Probabilistic Reward Task.Biological psychiatry global open science · 2026Article
- The kynurenine pathway in relation to depression and anhedonia symptom severity among women with HIV.Brain, behavior, & immunity - health · 2026Article
- Sex, drugs, and arousal-two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity.Therapeutic advances in psychopharmacology · 2026Article
- The cognitive neuroscience of ketamine in major depression.Brain : a journal of neurology · 2025Review
- Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens.Neuron · 2025Article
- Anhedonia: Current and future treatments.PCN reports : psychiatry and clinical neurosciences · 2025Review
- Towards an expanded neurocognitive account of ketamine's rapid antidepressant effects.The international journal of neuropsychopharmacology · 2025Review
- Advances in the study of apathy related to cerebral small vessel disease.Frontiers in neurology · 2025Review
- Insulin Resistance, Temperament and Personality Traits Are Associated with Anhedonia in a Transdiagnostic Sample.Brain sciences · 2024Article
- Licit use of illicit drugs for treating depression: the pill and the process.The Journal of clinical investigation · 2024Review
- Modulation of habenular and nucleus accumbens functional connectivity by ketamine in major depression.Brain and behavior · 2024Article
- Annual Research Review: Puberty and the development of anhedonia - considering childhood adversity and inflammation.Journal of child psychology and psychiatry, and allied disciplines · 2024Review
- The Patient's Perspective on the Effects of Intranasal Esketamine in Treatment-Resistant Depression.Brain sciences · 2023Article
- Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023Article
- Adaptive Circadian Rhythms for Autonomous and Biologically Inspired Robot Behavior.Biomimetics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anhedonia is a common, persistent, and disabling condition. However, available therapeutics primarily focus on the reduction of depressive and negative symptoms rather than amelioration of deficits in positive affect. As such, extant drug treatments remain largely ineffective in treating symptoms of anhedonia. Ketamine is a rapid-acting and novel therapeutic treatment for treatment-resistant depression, which has also been demonstrated to attenuate symptoms of anhedonia. However, the literature on the anti-anhedonic effects of ketamine is limited-especially within independent dimensions of this symptom domain. Herein, this review examined the impact of ketamine treatment on anhedonia and its dimensions on anticipatory, consummatory, and motivation-related reward deficits. Overall, the findings have shown a trend towards symptom reduction and/or improvements in anhedonia and their respective subdomains, in both human and preclinical studies, as well as its potential to provide additional benefit in reducing suicidality and improving quality-of-life. Although further research is required in understanding the long-term efficacy and mechanism, ketamine may provide an effective and rapid-acting therapeutic in an otherwise unmet domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.